Viral Gastroenteritis Market to Experience Exponential Growth by 2023

Posted by vinit sawant on April 23rd, 2021

Market Highlights

Viral gastroenteritis is one of the common gastrointestinal disease across the globe. It is a communicable disease transmitted through contaminated food or water and direct contact with the infected person. Notovirus is the common cause of viral gastritis in various developed and developing countries across the globe.

Rising prevalence of gastrointestinal disease across the globe, demand for new drugs for the treatment and increasing expenses on research and development in gastroenterology fuel the market growth. Additionally, the growing concerns about the spread of the disease among children and an urgent need to manage viral gastroenteritis also contribute to the market growth.

The global viral gastroenteritis market size is expected to grow at a CAGR of 7.5% during the forecast period.

Taste the market data and market information presented through more than 120 market data tables and figures spread over 206 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Viral gastroenteritis market research report–Global forecast till 2023.”

Major Players in Viral gastroenteritis Market

Some of the key players in the global market are Valeant Pharmaceuticals (U.S.), Janssen Global Services, LLC (U.S.), Takeda Pharmaceutical (Japan), Bayer AG (Germany), Sanofi (France), Allergan (Ireland), GlaxoSmithKline (U.S.), Abbott (U.S.),  and AstraZeneca (U.K).

Regional Analysis

America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center for Disease Control and Prevention (CDC), each year in the United States, there are nearly 19 to 21 million cases of acute gastroenteritis. Furthermore the prevalence of acute gastrointestinal diseases is found to be high in Canada.

Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.